Profile of NEUROSENSE THERAPEUTICS LTD(NASDAQ:NRSN) stock

NEUROSENSE THERAPEUTICS LTD1.63

NASDAQ:NRSN (2/3/2023, 7:00:03 PM)-0.02 (-1.21%)

After market: 1.58 -0.05 (-3.07%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	08-31 2022-08-31/bmo	Earnings (Next)	12-13 2022-12-13/bmo
Ins Owners	N/A	Inst Owners	N/A
Market Cap	19.03M	Shares	11.67M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.86
IPO	12-09 2021-12-09

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Company Info

NEUROSENSE THERAPEUTICS LTD

11 Hamenofim St., Building B

Herzliya

P: 97299531142.0

Employees: 11

Website: https://www.neurosense-tx.com/

NRSN News

16 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

17 days ago - InvestorPlaceWhy Is NeuroSense (NRSN) Stock Up 98% Today?

NeuroSense (NRSN) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease (AD).

17 days ago - Seeking AlphaNeuroSense Therapeutics surges 92% on Alzheimer's biomarker study results (NASDAQ:NRSN)

Microcap NeuroSense Therapeutics (NRSN) is up 92% in Thursday morning trading after the reporting positive results for a biomarker study of its combination platform therapy for Alzheimer's.

17 days ago - NeurosenseNeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

2 months ago - NeurosenseNeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

3 months ago - NeurosenseNeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS